Vivos Inc. announced that it has been notified by the FDA that RadioGel™ is classified as a device for animal therapy. The FDA also reviewed and approved its label, which is a requirement for any device used in animals. Based on the FDA recommendation, RadioGel™ will be marketed as IsoPet™ for use by veterinarians to avoid any confusion between animal and human therapy. Vivos already has trademark protection for the IsoPet name. In February, the company plans to start recruiting canine skin cancer patients to be treated at the University of Missouri, incorporating lessons learned at WSU. The animal therapy data generated from these studies will also be used in the pre-clinical data required by the FDA as part of the testing required for treating skin cancer in humans. After all the pre-clinical testing is completed the company will submit an Investigational Device Exemption to obtain permission to initiate human clinical trials.